中国P站

Primary bone tumors; Secondary bone tumors; Metastatic bone disease; Osteosarcoma; Chondrosarcoma; Bone metastases; Diagnosis; Treatment; Orthopaedic oncology; Multidisciplinary care

Introduction

Bone tumors, though relatively rare compared to other malignancies, represent a significant challenge in orthopedic and oncologic practice due to their complex biology and potential for severe morbidity. They are broadly categorized into primary tumors, originating within the bone itself, and secondary tumors, which are metastatic lesions from cancers elsewhere in the body [1]. Primary bone tumors can be benign or malignant, with common examples including osteosarcoma, Ewing sarcoma, and chondrosarcoma. In contrast, secondary bone tumors are almost always malignant and frequently arise from cancers of the breast, prostate, lung, kidney, and thyroid. The skeletal system, especially the spine, pelvis, and proximal long bones, is a common site for metastases, given its rich vascular supply and red marrow content [2]. A clear understanding of the spectrum of bone tumors is essential for timely diagnosis, effective management, and improved prognosis. This article delves into the biological differences between primary and secondary bone tumors, their clinical features, diagnostic workup, and contemporary management strategies. It also discusses future directions in bone tumor research and patient care [3].

Description

Primary bone tumors are those that originate from bone or its associated elements such as cartilage, fibrous tissue, or bone marrow. They are classified based on the cell of origin, histological characteristics, and behavior (benign or malignant). Osteosarcoma, the most common malignant primary bone tumor, typically affects adolescents and young adults and arises from primitive bone-forming mesenchymal cells. Chondrosarcoma, another major primary malignancy, usually occurs in older adults and arises from cartilaginous tissue. Ewing sarcoma, a small round blue cell tumor, affects children and young adults and may involve both bone and soft tissue. Benign primary bone tumors, such as osteoid osteoma, enchondroma, and giant cell tumor of bone, may still cause significant clinical issues due to pain, structural compromise, or risk of malignant transformation. Early recognition and appropriate intervention are necessary to prevent complications [4].

Secondary bone tumors, or bone metastases, are significantly more common than primary tumors and represent a major cause of morbidity in patients with advanced cancer. Metastatic bone disease often presents with bone pain, pathological fractures, spinal cord compression, or hypercalcemia. The most common primary sources include breast, prostate, and lung cancers. Prostate cancer tends to produce osteoblastic (bone-forming) lesions, whereas breast and lung cancers are often osteolytic (bone-destroying) [5]. The diagnostic approach for bone tumors typically includes a combination of imaging, laboratory studies, and biopsy. Plain radiographs can provide initial insights based on lesion location, margins, and matrix mineralization. MRI offers superior soft tissue contrast and is useful for local staging, while CT scans can delineate cortical bone involvement. PET-CT and bone scintigraphy are valuable for detecting metastatic disease. Definitive diagnosis requires histopathological examination obtained via image-guided core needle biopsy or open surgical biopsy [6].

Discussion

The management of primary and secondary bone tumors differs significantly and is guided by tumor type, location, extent of disease, and patient factors. Primary malignant bone tumors like osteosarcoma and Ewing sarcoma require multimodal treatment including neoadjuvant chemotherapy, wide surgical resection, and postoperative chemotherapy [7]. Limb-sparing surgery has become the standard of care, replacing amputation in many cases due to advances in surgical techniques and prosthetic reconstruction. Radiation therapy is limited in osteosarcoma due to radioresistance but plays a crucial role in Ewing sarcoma and certain benign aggressive tumors. For chondrosarcoma, which is largely chemo- and radioresistant, surgical resection remains the mainstay of treatment. In benign tumors, curettage, bone grafting, or en bloc resection may be indicated depending on the lesion’s aggressiveness. Management of secondary bone tumors focuses on palliation, maintaining skeletal integrity, and preserving function. Systemic therapy is tailored to the primary cancer and includes hormonal therapy, chemotherapy, targeted agents, or immunotherapy. Local control strategies include bisphosphonates or denosumab to reduce skeletal-related events, radiation therapy for pain relief, and surgical stabilization of impending or completed pathological fractures [8].

Emerging treatments are bridging the gap between primary and secondary tumor management. Stereotactic body radiation therapy (SBRT) offers high-dose, localized radiation with minimal collateral damage, beneficial in treating oligometastatic disease. Minimally invasive procedures like radiofrequency ablation and cementoplasty are gaining ground for pain relief and structural support [9]. Molecular profiling and genetic testing are increasingly guiding personalized therapy, especially in rare or treatment-refractory tumors. Multidisciplinary care involving orthopedic oncologists, medical and radiation oncologists, radiologists, pathologists, and rehabilitation specialists is essential for optimizing outcomes. Tumor boards ensure comprehensive evaluation and consensus-driven treatment plans tailored to individual patients [10].

Conclusion

Navigating the spectrum of primary and secondary bone tumors requires a nuanced understanding of their distinct pathophysiological mechanisms, clinical presentations, and treatment paradigms. While primary bone tumors demand aggressive and often curative intent interventions, secondary bone tumors necessitate a palliative approach with an emphasis on quality of life. The expanding role of precision medicine, advanced imaging, and multidisciplinary collaboration continues to refine diagnosis and management, offering hope for improved survival and function. Ongoing research into tumor biology, immune interactions, and targeted therapies promises to enhance the future landscape of care for patients with bone neoplasms.

References

1. Ingadottir AR, Bjorgvinsdottir EB, Beck A, Baldwin C, Weekes C, et al. (2020) . Clin Nutr 39: 1085-1091.

   , ,

2. Ogan N, Y谋ld谋r谋m F, Süzen B, Baha A, Akp谋nar EE, et al. (2020) . Turkish Thorac J 21: 49-53.

3. Maia I, Peleteiro B, Xará S, Amaral TF (2017) . J Am Coll Nutr 36: 137-147.

   , ,

4. Law S, Kumar P, Woods S, Sriram KB (2016) . Hosp Pract (1995) 44: 207-212.

   , ,

5. Vermeeren MA, Schols AM, Wouters EF (1997) . Eur Respir J 10: 2264-2269.

   , ,

6. van Bokhorst-de, Guaitoli PR, Jansma EP, De-Vet HCW (2014) . Clin Nutr 33: 39-58.

   , ,

7. Kovelis D, Segretti N, Probst V, Lareau S, Brunetto A, et al. (2008) . J Bras Pneumol 34: 1008-1018.

   , ,

8. Fischer M, JeVenn A, Hipskind P (2015) . Nutr Clin Pract 30: 239-248.

   , ,

9. Landis J, Koch GG (1977) . Biometrics 33: 159-174.

   , ,

10. Neelemaat F, Meijers J, Kruizenga H, Ballegooijen HV, van Bokhorst-de van der Schueren M, et al. (2011) . J Clin Nurs 20: 2144-2152.

    , ,